Search - tctmd.com

Displaying 101 - 120 of 389

Sort: Relevancy | Date

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Ted Feldman

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Portico: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Raj Makkar

November 01, 2016

Presentation TCT 2016

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Dmitriy N. Feldman, Emmanouil S. Brilakis

November 01, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Presenter: Philip M. Urban, Stephen G. Worthley, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Jeffrey J. Popma

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

Presentation TCT 2016

Complications Related to Contrast and Commonly Used Medications

Presenter: Giora Weisz, Payam Dehghani

November 01, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Statistics and Clinical Study Design: Teaching Through Experience

Presenter: Stuart J. Pocock, Binita Shah

November 01, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

Presentation TCT 2016

2016 CTO Revascularization Update

Presenter: Sripal Bangalore, George D. Dangas, Khaldoon Alaswad

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

2016 STEMI PCI Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Sanjit S. Jolly

November 01, 2016

Advertisement

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Portico: Design Features, Special Attributes, and Clinical Trial Program

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

FDA Perspectives on Short DAPT IDE Trials

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Complications Related to Contrast and Commonly Used Medications

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Statistics and Clinical Study Design: Teaching Through Experience

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

2016 CTO Revascularization Update

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

2016 STEMI PCI Update: Evidence and Guidelines

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content